Omalizumab use during pregnancy for CIU: a tertiary care experience.
Publication
, Journal Article
Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C
Published in: European annals of allergy and clinical immunology
July 2016
The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.
Duke Scholars
Published In
European annals of allergy and clinical immunology
ISSN
1764-1489
Publication Date
July 2016
Volume
48
Issue
4
Start / End Page
145 / 146
Related Subject Headings
- Urticaria
- Treatment Outcome
- Tertiary Care Centers
- Risk Assessment
- Remission Induction
- Pregnancy Complications
- Pregnancy
- Omalizumab
- Ohio
- Immunosuppressive Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Cuervo-Pardo, L., Barcena-Blanch, M., & Radojicic, C. (2016). Omalizumab use during pregnancy for CIU: a tertiary care experience. European Annals of Allergy and Clinical Immunology, 48(4), 145–146.
Cuervo-Pardo, L., M. Barcena-Blanch, and C. Radojicic. “Omalizumab use during pregnancy for CIU: a tertiary care experience.” European Annals of Allergy and Clinical Immunology 48, no. 4 (July 2016): 145–46.
Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. European annals of allergy and clinical immunology. 2016 Jul;48(4):145–6.
Cuervo-Pardo, L., et al. “Omalizumab use during pregnancy for CIU: a tertiary care experience.” European Annals of Allergy and Clinical Immunology, vol. 48, no. 4, July 2016, pp. 145–46.
Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. European annals of allergy and clinical immunology. 2016 Jul;48(4):145–146.
Published In
European annals of allergy and clinical immunology
ISSN
1764-1489
Publication Date
July 2016
Volume
48
Issue
4
Start / End Page
145 / 146
Related Subject Headings
- Urticaria
- Treatment Outcome
- Tertiary Care Centers
- Risk Assessment
- Remission Induction
- Pregnancy Complications
- Pregnancy
- Omalizumab
- Ohio
- Immunosuppressive Agents